Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.62 |
| ▸ | FNTB | P49356 | 6/20 | 0.62 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 10/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416179 | 0.95 | BACE1 (0.63) | FNTAFNTBBACE1BACE2CTSD | |
| SCHEMBL30051569 | 0.92 | FNTA (0.71) | FNTAFNTBPGGT1B | |
| SCHEMBL30051749 | 0.92 | FNTA (0.61) | FNTAFNTBPGGT1B | |
| SCHEMBL30646305 | 0.91 | BACE1 (0.64) | FNTAFNTBBACE1BACE2CTSD | |
| SCHEMBL10435395 | 0.91 | FNTA (0.60) | FNTAFNTBPGGT1BBACE1BACE2 | |
| SCHEMBL10435396 | 0.91 | FNTA (0.60) | FNTAFNTBPGGT1BBACE1BACE2 | |
| SCHEMBL30532235 | 0.91 | FNTA (0.62) | FNTAFNTBPGGT1BBACE1 | |
| SCHEMBL30917374 | 0.90 | FNTA (0.56) | FNTAFNTBPGGT1BBACE1BACE2 | |
| SCHEMBL29769731 | 0.89 | LTA4H (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL12519269 | 0.89 | FNTA (0.78) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353898-A1 | SERPIN PEPTIDE DERIVATIVES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250161419-A1 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC | 2025-05-22 | — | — | US | claimed |
| EP-4514838-A1 | SERPIN PEPTIDE DERIVATIVES AND METHODS OF USING THE SAME | Serpin Pharma, LLC (US) | 2025-03-05 | — | — | EP | claimed |
| CN-119497719-A | SERPIN peptide derivatives and methods of use thereof | 赛品制药有限责任公司 | 2025-02-21 | — | — | CN | claimed |
| EP-4460322-A2 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | Serpin Pharma, LLC (US) | 2024-11-13 | — | — | EP | claimed |
| CN-118804758-A | SERPIN peptides and methods of use thereof | 赛品制药有限责任公司 | 2024-10-18 | — | — | CN | claimed |
| US-20230406906-A1 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC | 2023-12-21 | — | — | US | claimed |
| WO-2023212661-A1 | SERPIN PEPTIDE DERIVATIVES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023133078-A2 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC (US) | 2023-07-13 | — | — | WO | claimed |
| EP-4003391-A2 | PEPTIDES AND METHODS OF USING THE SAME | Serpin Pharma, LLC (US) | 2022-06-01 | — | — | EP | claimed |
| US-20250353898-A1 | SERPIN PEPTIDE DERIVATIVES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250228922-A1 | METHODS FOR TREATMENT OF DISEASES | SERPIN PHARMA, LLC | 2025-07-17 | — | — | US | disclosed |
| US-20250195630-A1 | COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR TREATMENT OF GRAFT VERSUS HOST DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-19 | — | — | US | disclosed |
| US-20250161419-A1 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC | 2025-05-22 | — | — | US | disclosed |
| US-20250101131-A1 | COMPOSITIONS AND METHODS OF USE FOR ALPHA-1 ANTITRYPSIN FUSION POLYPEPTIDES | KONKUK UNIVERSITY (KR) | 2025-03-27 | — | — | US | disclosed |
| US-11779630-B2 | Peptides and methods of using the same | SERPIN PHARMA, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023133078-A2 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20220265761-A1 | PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA, LLC | 2022-08-25 | — | — | US | disclosed |
| US-20220204646-A1 | Compositions and Methods of Use of Alpha-1 Antitrypsin Fusion Polypeptides | KONKUK UNIVERSITY (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-4003391-A2 | PEPTIDES AND METHODS OF USING THE SAME | Serpin Pharma, LLC (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353898-A1 | SERPIN PEPTIDE DERIVATIVES AND METHODS OF USING THE SAME | SERPINE1, SERPINA2, SERPINB10 | FNTA 3744/4885FNTB 3029/4885PGGT1B 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.